With the help of Medscape, SamaCare has conducted our second annual survey asking specialty providers key questions regarding their experiences with prior authorizations, the support they get from pharmaceutical market access teams in handling prior authorizations, and the impact the process has on patients. Read our key takeaways below, and scroll down for full survey results.
For most, the prior authorization burden has increased and efficiency in handling prior authorizations has decreased
Of providers surveyed this year, 67% report their prior authorization burden has increased “significantly” or “somewhat” over the last 12 months. While overall practice efficiency in managing prior authorizations has declined year-over-year with a +10pt increase in practices reporting they are “somewhat inefficient” or “highly inefficient” at navigating the prior authorization process, there was also a small uptick in practices reporting they have a “highly efficient” prior authorization process (+6pt), suggesting a split in terms of practices who have adopted new processes or technologies to address the increased burden.
More providers believe the prior authorization process is hurting patients
While overall providers views on the impact of the prior authorization process on patient care, adherence, and outcomes has remained relatively stable and predominantly negative year-over-year, there was a +20pt uptick in the percentage of providers who indicate the prior authorization process has a “highly negative” impact on patient care compared to last year. This percentage seems to have shifted from the “somewhat negative” response category.
Awareness of market access services has waned during a challenging year
The percentage of respondents who indicated they are “highly aware” or “somewhat aware” of market access services provided by drug companies has waned year over year (-9pt).This may stem from the difficulties in reaching practices with educational messages during the chaos surrounding the last year of the pandemic. However, there has been a slight uptick in engagement with market access teams among practices who are aware (+4pt).
The prior authorization process impacts providers likelihood to prescribe a medication
An overwhelming majority of respondents (91% in 2022) “highly agree” or “somewhat agree” that consistent prior authorization delays or denials would impact their likelihood to prescribe a drug if there was an equally effective alternative in the market.
Less than half of practices are confident drug companies can help with prior auths
Confidence in drug companies effectiveness at troubleshooting prior authorizations has remained stable year-over-year, with 41% of practices stating drug companies are “always effective” or “often effective” compared to 40% in 2021.
This year, we looked at the differences in responses between solo practices and group practices, government hospitals, and non-government hospitals. Across the board, the data shows solo practices are particularly challenged when dealing with the prior authorization process. Solo practices were more likely to report their prior authorization burden increased in the past 12 months (75%) compared to the average across practice types (67%). Solo practices were also far less likely to feel at least “somewhat efficient” at navigating prior authorizations (33%) compared to the average across practice types (74%).
With the help of Medscape, SamaCare has conducted our second annual survey asking specialty providers key questions regarding their experiences with prior authorizations, the support they get from pharmaceutical market access teams in handling prior authorizations, and the impact the process has on patients. Read our key takeaways below, and scroll down for full survey results.
For most, the prior authorization burden has increased and efficiency in handling prior authorizations has decreased
Of providers surveyed this year, 67% report their prior authorization burden has increased “significantly” or “somewhat” over the last 12 months. While overall practice efficiency in managing prior authorizations has declined year-over-year with a +10pt increase in practices reporting they are “somewhat inefficient” or “highly inefficient” at navigating the prior authorization process, there was also a small uptick in practices reporting they have a “highly efficient” prior authorization process (+6pt), suggesting a split in terms of practices who have adopted new processes or technologies to address the increased burden.
More providers believe the prior authorization process is hurting patients
While overall providers views on the impact of the prior authorization process on patient care, adherence, and outcomes has remained relatively stable and predominantly negative year-over-year, there was a +20pt uptick in the percentage of providers who indicate the prior authorization process has a “highly negative” impact on patient care compared to last year. This percentage seems to have shifted from the “somewhat negative” response category.
Awareness of market access services has waned during a challenging year
The percentage of respondents who indicated they are “highly aware” or “somewhat aware” of market access services provided by drug companies has waned year over year (-9pt).This may stem from the difficulties in reaching practices with educational messages during the chaos surrounding the last year of the pandemic. However, there has been a slight uptick in engagement with market access teams among practices who are aware (+4pt).
The prior authorization process impacts providers likelihood to prescribe a medication
An overwhelming majority of respondents (91% in 2022) “highly agree” or “somewhat agree” that consistent prior authorization delays or denials would impact their likelihood to prescribe a drug if there was an equally effective alternative in the market.
Less than half of practices are confident drug companies can help with prior auths
Confidence in drug companies effectiveness at troubleshooting prior authorizations has remained stable year-over-year, with 41% of practices stating drug companies are “always effective” or “often effective” compared to 40% in 2021.
This year, we looked at the differences in responses between solo practices and group practices, government hospitals, and non-government hospitals. Across the board, the data shows solo practices are particularly challenged when dealing with the prior authorization process. Solo practices were more likely to report their prior authorization burden increased in the past 12 months (75%) compared to the average across practice types (67%). Solo practices were also far less likely to feel at least “somewhat efficient” at navigating prior authorizations (33%) compared to the average across practice types (74%).
With the help of Medscape, SamaCare has conducted our second annual survey asking specialty providers key questions regarding their experiences with prior authorizations, the support they get from pharmaceutical market access teams in handling prior authorizations, and the impact the process has on patients. Read our key takeaways below, and scroll down for full survey results.
For most, the prior authorization burden has increased and efficiency in handling prior authorizations has decreased
Of providers surveyed this year, 67% report their prior authorization burden has increased “significantly” or “somewhat” over the last 12 months. While overall practice efficiency in managing prior authorizations has declined year-over-year with a +10pt increase in practices reporting they are “somewhat inefficient” or “highly inefficient” at navigating the prior authorization process, there was also a small uptick in practices reporting they have a “highly efficient” prior authorization process (+6pt), suggesting a split in terms of practices who have adopted new processes or technologies to address the increased burden.
More providers believe the prior authorization process is hurting patients
While overall providers views on the impact of the prior authorization process on patient care, adherence, and outcomes has remained relatively stable and predominantly negative year-over-year, there was a +20pt uptick in the percentage of providers who indicate the prior authorization process has a “highly negative” impact on patient care compared to last year. This percentage seems to have shifted from the “somewhat negative” response category.
Awareness of market access services has waned during a challenging year
The percentage of respondents who indicated they are “highly aware” or “somewhat aware” of market access services provided by drug companies has waned year over year (-9pt).This may stem from the difficulties in reaching practices with educational messages during the chaos surrounding the last year of the pandemic. However, there has been a slight uptick in engagement with market access teams among practices who are aware (+4pt).
The prior authorization process impacts providers likelihood to prescribe a medication
An overwhelming majority of respondents (91% in 2022) “highly agree” or “somewhat agree” that consistent prior authorization delays or denials would impact their likelihood to prescribe a drug if there was an equally effective alternative in the market.
Less than half of practices are confident drug companies can help with prior auths
Confidence in drug companies effectiveness at troubleshooting prior authorizations has remained stable year-over-year, with 41% of practices stating drug companies are “always effective” or “often effective” compared to 40% in 2021.
This year, we looked at the differences in responses between solo practices and group practices, government hospitals, and non-government hospitals. Across the board, the data shows solo practices are particularly challenged when dealing with the prior authorization process. Solo practices were more likely to report their prior authorization burden increased in the past 12 months (75%) compared to the average across practice types (67%). Solo practices were also far less likely to feel at least “somewhat efficient” at navigating prior authorizations (33%) compared to the average across practice types (74%).
With the help of Medscape, SamaCare has conducted our second annual survey asking specialty providers key questions regarding their experiences with prior authorizations, the support they get from pharmaceutical market access teams in handling prior authorizations, and the impact the process has on patients. Read our key takeaways below, and scroll down for full survey results.
For most, the prior authorization burden has increased and efficiency in handling prior authorizations has decreased
Of providers surveyed this year, 67% report their prior authorization burden has increased “significantly” or “somewhat” over the last 12 months. While overall practice efficiency in managing prior authorizations has declined year-over-year with a +10pt increase in practices reporting they are “somewhat inefficient” or “highly inefficient” at navigating the prior authorization process, there was also a small uptick in practices reporting they have a “highly efficient” prior authorization process (+6pt), suggesting a split in terms of practices who have adopted new processes or technologies to address the increased burden.
More providers believe the prior authorization process is hurting patients
While overall providers views on the impact of the prior authorization process on patient care, adherence, and outcomes has remained relatively stable and predominantly negative year-over-year, there was a +20pt uptick in the percentage of providers who indicate the prior authorization process has a “highly negative” impact on patient care compared to last year. This percentage seems to have shifted from the “somewhat negative” response category.
Awareness of market access services has waned during a challenging year
The percentage of respondents who indicated they are “highly aware” or “somewhat aware” of market access services provided by drug companies has waned year over year (-9pt).This may stem from the difficulties in reaching practices with educational messages during the chaos surrounding the last year of the pandemic. However, there has been a slight uptick in engagement with market access teams among practices who are aware (+4pt).
The prior authorization process impacts providers likelihood to prescribe a medication
An overwhelming majority of respondents (91% in 2022) “highly agree” or “somewhat agree” that consistent prior authorization delays or denials would impact their likelihood to prescribe a drug if there was an equally effective alternative in the market.
Less than half of practices are confident drug companies can help with prior auths
Confidence in drug companies effectiveness at troubleshooting prior authorizations has remained stable year-over-year, with 41% of practices stating drug companies are “always effective” or “often effective” compared to 40% in 2021.
This year, we looked at the differences in responses between solo practices and group practices, government hospitals, and non-government hospitals. Across the board, the data shows solo practices are particularly challenged when dealing with the prior authorization process. Solo practices were more likely to report their prior authorization burden increased in the past 12 months (75%) compared to the average across practice types (67%). Solo practices were also far less likely to feel at least “somewhat efficient” at navigating prior authorizations (33%) compared to the average across practice types (74%).
